Reevaluating the Necessity of Transplant in the Modern Myeloma Era

In an interview on the ATLAS trial (NCT02659293), Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, considers the evolving role of autologous stem cell transplantation (ASCT) in multiple myeloma, noting that the medical community is on the verge of identifying patient subgroups who may be able to achieve optimal outcomes without undergoing this intensive procedure. Although he emphasizes that the current standard of care for transplant-eligible patients remains induction therapy followed by consolidation with high-dose melphalan and maintenance, he argues that there are significant clinical and personal considerations that warrant a more personalized approach.

The first consideration involves the patient experience and the inherent toxicity of high-dose chemotherapy. Melphalan, despite being refined over decades of use, remains a grueling treatment that many patients approach with considerable trepidation. The physical and psychological burden of undergoing such a high-intensity procedure early in the disease course is a factor that Jakubowiak insists should not be minimized. For many, the prospect of a transplant represents a daunting hurdle that impacts their overall quality of life during the early phases of treatment.

Perhaps more critical than the immediate toxicity is the long-term risk of secondary malignancies. It is well-documented that exposure to high-dose melphalan and the transplant process increases the statistical risk of developing secondary cancers, such as leukemia. Dr. Jakubowiak posits that if a transplant is not absolutely needed for a specific patient to achieve a durable remission, subjecting them to these long-term oncogenic risks may be counterproductive. This is especially relevant in an era where modern induction and maintenance regimens, such as the carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) triplet used in the ATLAS trial are achieving unprecedented depths of response.

Ultimately, the goal of current research is to move toward a more nuanced, risk-stratified strategy. If clinicians can accurately define a “good-risk” group potentially through sustained minimal residual disease negativity or specific cytogenetic profiles, these patients might benefit from extended, high-intensity systemic therapy while avoiding the immediate and long-term risks associated with a transplant. Jakubowiak concludes that defining these populations is a priority, as allowing certain patients to bypass transplantation could significantly improve their long-term health and treatment satisfaction.